Hepatocellular Carcinoma – Landscape & Forecast – Disease Landscape & Forecast

Hepatocellular carcinoma remains a challenging disease with a complex underlying etiology. Although angiogenesis inhibitors, including Nexavar (Bayer / Amgen), Stivarga (Bayer), Lenvima (Eisai / Merck & Co.), Cabometyx (Exelixis / Ipsen / Takeda), and Cyramza (Eli Lilly), have been central to the treatment of advanced disease, the market will change substantially over the next 10 years following the 2020 approval of Tecentriq (Roche / Genentech) plus bevacizumab, the FDA’s accelerated approval of Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical), and the anticipated entry of novel immune checkpoint inhibitor-based combinations. The uptake of these premium-priced regimens and their expected label expansion into the untapped early-stage setting will drive robust growth of hepatocellular carcinoma therapy sales.

Questions answered

  • What are the current therapies for hepatocellular carcinoma, and what are the main unmet needs?
  • How large are market-relevant drug-treatable populations, and how will drug-treatment rates change over time?
  • What is the expected market impact of recent and forecast drug approvals on the various subpopulations of hepatocellular carcinoma? What are interviewed experts’ insights on key existing and emerging agents?
  • What are the key factors driving or constraining market growth?

Content highlights

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 19 country-specific interviews with thought-leading medical oncologists.

Key companies: Bayer HealthCare / Amgen / Onyx, Bristol Myers Squibb / Ono Pharmaceutical, Merck & Co., Eisai, Exelixis / Ipsen, Eli Lilly, Roche / Genentech.

Key drugs: Nexavar, Lenvima, Stivarga, Cabometyx, Cyramza, Avastin, Tecentriq, Opdivo, Yervoy, Keytruda.

Population segments in the market forecast: early-stage, first-line intermediate-stage, second-line intermediate-stage, first-line advanced-stage, and second-line advanced-stage hepatocellular carcinoma.

Emerging therapies: Phase III/PR: 6 drugs; coverage of select Phase I and Phase II products.

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Hepatocellular Carcinoma - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q2 2022
        • April 2022
      • Q1 2022
        • March 2022
        • February 2022
        • January 2022
      • Q4 2021
        • December 2021
        • November 2021
      • Q3 2021
        • August 2021
        • July 2021
      • Q2 2021
        • June 2021
        • May 2021
    • Key Findings
      • Market Outlook
        • Key Findings
          • Market Share of Drug Classes for Hepatocellular Carcinoma: 2020
          • Market Share of Drug Classes for Hepatocellular Carcinoma: 2030
          • Drug-Treatable Population Share and Major-Market Sales Share in Hepatocellular Carcinoma: 2020
          • Drug-Treatable Population Share and Major-Market Sales Share in Hepatocellular Carcinoma: 2030
          • Current Therapies with Sales Potential in Hepatocellular Carcinoma: Population Positioning
          • Emerging Therapies With Sales Potential in Hepatocellular Carcinoma: Population Positioning
          • Hepatocellular Carcinoma SWOT Analysis
        • Market Drivers and Constraints
          • What Factors Are Driving the Market for Hepatocellular Carcinoma?
          • What Factors Are Constraining the Market for Hepatocellular Carcinoma?
          • Major-Market Sales for Hepatocellular Carcinoma by Drug-Treatable Population: 2020-2030
          • Major-Market Sales of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: 2020-2030
          • Major-Market Sales of Angiogenesis Inhibitors for Hepatocellular Carcinoma: 2020-2030
        • Segment-Specific Trends
          • Patient-Share Dynamics of Therapies for Early-Stage Hepatocellular Carcinoma in the United States: 2020-2030
          • Patient-Share Dynamics of Therapies in First-Line Intermediate-Stage Hepatocellular Carcinoma in the United States: 2020-2030
          • Patient-Share Dynamics of Therapies in Second-Line Intermediate-Stage Hepatocellular Carcinoma in the United States: 2020-2030
          • Patient-Share Dynamics of Therapies in First-Line Advanced-Stage Hepatocellular Carcinoma in the United States: 2020-2030
          • Patient-Share Dynamics of Therapies in Second-Line Advanced-Stage Hepatocellular Carcinoma in the United States: 2020-2030
      • Forecast
        • Market Forecast Downloads
        • Market Forecast Assumptions
        • Market Forecast Dashboard
      • Etiology and Pathophysiology
        • Disease Overview
          • Etiology
            • Key Risk Factors Associated With the Development of Hepatocellular Carcinoma
          • Disease Pathophysiology
            • Liver Anatomy and Tumorigenesis
            • Hepatocellular Carcinoma Pathogenesis
          • Staging and Classification
            • American Joint Committee on Cancer Tumor Node Metastasis Staging
            • Barcelona Clinic Liver Cancer Staging Criteria
            • Child-Pugh Score
            • Liver Cancer Study Group of Japan Tumor Node Metastasis Staging
            • Liver Damage Score
            • Evidence-Based Algorithm for Hepatocellular Carcinoma
          • Key Pathways and Drug Targets
            • Drug Targets and Potential Therapies for Hepatocellular Carcinoma
            • Drug Targets for Hepatocellular Carcinoma
            • Biology of Immune Checkpoint Inhibitors and Modulators
        • Epidemiology
          • Key Findings
            • Epidemiology Populations
              • Disease Definition
              • Methods
              • Sources Used for Diagnosed Incidence of Hepatocellular Carcinoma
              • Diagnosed Incident Cases of Hepatocellular Carcinoma: 2020-2030
              • Disease Definition
              • Methods
              • Sources Used for Stage Distribution of Hepatocellular Carcinoma
              • Diagnosed Incident Cases of Hepatocellular Carcinoma by Stage Distribution: 2020-2030
              • Definition
              • Methods
              • Sources Used for Recurrent Incidence of Hepatocellular Carcinoma
              • Recurrent Incident Cases of Hepatocellular Carcinoma: 2020-2030
              • Hepatocellular Carcinoma Patient Flow
              • Drug-Treatable Cases: 2020-2030
              • Drug-Treated Cases: 2020-2030
          • Current Treatment
            • Key Findings
              • Treatment Goals
                • Key Endpoints Used in Clinical Trials for Hepatocellular Carcinoma
              • Key Current Therapies
                • Overview
                • Mechanism of Action of Key Current Drug Classes Used for Hepatocellular Carcinoma
                • Current Treatments Used for Hepatocellular Carcinoma
                • Market Events Impacting the Use of Key Current Therapies for Hepatocellular Carcinoma
                • Key Results From Select Clinical Trials Investigating Nexavar for the Treatment of Hepatocellular Carcinoma
                • Ongoing Clinical Development of Nexavar
                • Key Ongoing Clinical Trials of Nexavar in the Treatment of Hepatocellular Carcinoma
                • Expert Insight: Nexavar
                • Key Results From Select Clinical Trials Investigating Stivarga for the Treatment of Hepatocellular Carcinoma
                • Ongoing Clinical Development of Stivarga
                • Key Ongoing Clinical Trials of Stivarga in the Treatment of Hepatocellular Carcinoma
                • Expert Insight: Stivarga
                • Key Results From Select Clinical Trials Investigating Lenvima for the Treatment of Hepatocellular Carcinoma
                • Ongoing Clinical Development of Lenvima
                • Key Ongoing Clinical Trials of Lenvima in the Treatment of Hepatocellular Carcinoma
                • Expert Insight: Lenvima
                • Key Results From Select Clinical Trials Investigating Cabometyx for the Treatment of Hepatocellular Carcinoma
                • Ongoing Clinical Development of Cabometyx
                • Key Ongoing Clinical Trials of Cabometyx in the Treatment of Hepatocellular Carcinoma
                • Expert Insight: Cabometyx
                • Key Results From Select Clinical Trials Investigating Cyramza for the Treatment of Hepatocellular Carcinoma
                • Ongoing Clinical Development Program for Cyramza
                • Expert Insight: Cyramza
                • Key Results From Select Clinical Trials Investigating Opdivo (With or Without Yervoy) for the Treatment of Hepatocellular Carcinoma
                • Ongoing Clinical Development of Opdivo (With or Without Yervoy)
                • Key Ongoing Clinical Trials of Opdivo (With or Without Yervoy) in the Treatment of Hepatocellular Carcinoma
                • Expert Insight: Opdivo (With or Without Yervoy)
                • Key Results From Select Clinical Trials Investigating Keytruda for the Treatment of Hepatocellular Carcinoma
                • Ongoing Clinical Development of Keytruda
                • Key Ongoing Clinical Trials of Keytruda in the Treatment of Hepatocellular Carcinoma
                • Expert Insight: Keytruda
                • Key Results From Select Clinical Trials Investigating Tecentriq for the Treatment of Hepatocellular Carcinoma
                • Ongoing Clinical Development Program for Tecentriq
                • Key Ongoing Clinical Trials of Tecentriq in the Treatment of Hepatocellular Carcinoma
                • Expert Insight: Tecentriq
              • Medical Practice
                • u200bEarly-Stage Hepatocellular Carcinoma
                • Intermediate-Stage Hepatocellular Carcinoma
                • Advanced-Stage Hepatocellular Carcinoma
                • Patient Characteristics Influencing Drug Selection in Hepatocellular Carcinoma
                • Treatment Decision Tree for Hepatocellular Carcinoma: United States
                • Treatment Decision Tree for Hepatocellular Carcinoma: Europe
                • Treatment Decision Tree for Hepatocellular Carcinoma: Japan
            • Unmet Need Overview
              • Current and Future Attainment of Unmet Needs in Hepatocellular Carcinoma
              • Top Unmet Needs in Hepatocellular Carcinoma: Current and Future Attainment
              • Expert Insight: Unmet Need in Hepatocellular Carcinoma
            • Emerging Therapies
              • Key Findings
                • Key Emerging Therapies
                  • Key Therapies in Development for Hepatocellular Carcinoma
                  • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Hepatocellular Carcinoma
                  • Key Results From Select Clinical Trials Investigating Imfinzi for the Treatment of Hepatocellular Carcinoma
                  • Key Ongoing Clinical Trials of Imfinzi in the Treatment of Hepatocellular Carcinoma
                  • Analysis of the Clinical Development Program for Imfinzi
                  • Expert Insight: Imfinzi
                  • Expectations for Market Authorization and Sales Opportunity of Imfinzi in Hepatocellular Carcinoma
                  • Analysis of the Clinical Development Program for Tremelimumab
                  • Expectations for Market Authorization and Sales Opportunity of Tremelimumab in Hepatocellular Carcinoma
                  • Key Results From Select Clinical Trials Investigating Tislelizumab for the Treatment of Hepatocellular Carcinoma
                  • Key Ongoing Clinical Trials of Tislelizumab in the Treatment of Hepatocellular Carcinoma
                  • Analysis of the Clinical Development Program for Tislelizumab
                  • Expert Insight: Tislelizumab
                  • Expectations for Market Authorization and Sales Opportunity of Tislelizumab in Hepatocellular Carcinoma
                  • Key Ongoing Clinical Trials of Camrelizumab in the Treatment of Hepatocellular Carcinoma
                  • Analysis of the Clinical Development Program for Camrelizumab
                  • Key Results From Select Clinical Trials Investigating Camrelizumab for the Treatment of Hepatocellular Carcinoma
                  • Expectations for Market Authorization and Sales Opportunity of Camrelizumab in Hepatocellular Carcinoma
                  • Key Ongoing Clinical Trials of EQ-176 in the Treatment of Hepatocellular Carcinoma
                  • Analysis of the Clinical Development Program for EQ176
                  • Key Results From Select Clinical Trials Investigating EQ-176 for the Treatment of Hepatocellular Carcinoma
                  • Expectations for Market Authorization and Sales Opportunity of EQ-176 in Hepatocellular Carcinoma
                  • Analysis of the Clinical Development Program for Rivoceranib
                  • Expectations for Market Authorization and Sales Opportunity of Rivoceranib in Hepatocellular Carcinoma
                  • Key Results From Select Clinical Trials Investigating Namodenoson for the Treatment of Hepatocellular Carcinoma
                  • Analysis of the Clinical Development Program for Namodenoson
                  • Key Ongoing Clinical Trials of Namodenoson in the Treatment of Hepatocellular Carcinoma
                  • Expectations for Market Authorization and Sales Opportunity of Namodenoson in Hepatocellular Carcinoma
                • Early-Phase Pipeline Analysis
                  • Select Compounds in Early-Phase Development for Hepatocellular Carcinoma
              • Access & Reimbursement Overview
                • Region-Specific Reimbursement Practices
                  • Key Market Access Considerations in Hepatocellular Carcinoma: United States
                  • General Reimbursement Environment: United States
                  • Key Market Access Considerations in Hepatocellular Carcinoma: EU5
                  • General Reimbursement Environment: EU5
                  • Key Market Access Considerations in Hepatocellular Carcinoma: Japan
                  • General Reimbursement Environment: Japan
              • Appendix
                • Hepatocellular Carcinoma Bibliography

            launch Related Market Assessment Reports